| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/13685538.2012.729110 |
| P698 | PubMed publication ID | 23067307 |
| P50 | author | Aled Rees | Q57037653 |
| Stefan Arver | Q43786742 | ||
| P2093 | author name string | Ignacio Moncada | |
| Bruno Lunenfeld | |||
| Heinrich M Schulte | |||
| P2860 | cites work | Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. | Q46979394 |
| Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life | Q48607948 | ||
| Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. | Q50775869 | ||
| Late-Onset Hypogonadism | Q56625177 | ||
| Testosterone therapy in the aging male | Q58249332 | ||
| Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices | Q28295533 | ||
| Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden | Q33239089 | ||
| Commentary: Guideline for male testosterone therapy: a regulatory perspective | Q33272516 | ||
| The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. | Q33599598 | ||
| Androgens and abdominal obesity | Q33637767 | ||
| Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency | Q33897720 | ||
| Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data | Q33933572 | ||
| Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). | Q33990779 | ||
| Testosterone and depression: systematic review and meta-analysis | Q34018597 | ||
| Identification of late-onset hypogonadism in middle-aged and elderly men. | Q34022776 | ||
| Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). | Q34063853 | ||
| Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline | Q34119261 | ||
| Testosterone and metabolic syndrome: a meta-analysis study | Q34135149 | ||
| A practical guide to male hypogonadism in the primary care setting | Q34167760 | ||
| Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). | Q34718357 | ||
| Clinical practice. Osteoporosis in men. | Q34767180 | ||
| Prevalence of hypogonadism in males aged at least 45 years: the HIM study | Q35037892 | ||
| Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts | Q35137175 | ||
| Testosterone therapy increased muscle mass and lipid oxidation in aging men. | Q35678129 | ||
| Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. | Q35862931 | ||
| Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis | Q36226107 | ||
| Review of Testim gel. | Q36407388 | ||
| Lower urinary-tract symptoms and testosterone in elderly men | Q36839032 | ||
| Low serum testosterone increases mortality risk among male dialysis patients. | Q37123233 | ||
| Relation between serum testosterone, serum estradiol, sex hormone-binding globulin, and geometrical measures of adult male proximal femur strength | Q37189981 | ||
| The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction | Q37222063 | ||
| Current guidelines for the diagnosis of testosterone deficiency. | Q37326190 | ||
| Testosterone undecanoate in the treatment of male hypogonadism | Q37773998 | ||
| Hypogonadism, Erectile Dysfunction, and Type 2 Diabetes Mellitus: What the Clinician Needs to Know | Q37810422 | ||
| Male late-onset hypogonadism: pathogenesis, diagnosis and treatment | Q37866630 | ||
| Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations | Q37869169 | ||
| Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males | Q39351891 | ||
| Sexual functioning and satisfaction in nonresponders to testosterone gel: Potential effectiveness of retreatment in hypogonadal males | Q39351896 | ||
| Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency | Q39656712 | ||
| Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone | Q39656717 | ||
| Prevalence of symptomatic androgen deficiency in men. | Q40183474 | ||
| Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study* | Q41140274 | ||
| High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden | Q42726184 | ||
| A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months | Q42792854 | ||
| Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients | Q42925108 | ||
| Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity | Q44210279 | ||
| A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function | Q44339663 | ||
| Important effect of food on the bioavailability of oral testosterone undecanoate | Q44356205 | ||
| Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel | Q44389267 | ||
| AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function | Q44467064 | ||
| Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone | Q44973547 | ||
| The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study | Q45145832 | ||
| Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study | Q45173585 | ||
| Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy | Q45739772 | ||
| Testosterone treatment and mortality in men with low testosterone levels. | Q45909072 | ||
| Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism | Q46318580 | ||
| The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism | Q46343590 | ||
| ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males | Q46397195 | ||
| Comparison of screening questionnaires for the diagnosis of hypogonadism | Q46685408 | ||
| Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study | Q46757585 | ||
| Testosterone and estradiol among older men. | Q46861767 | ||
| Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study | Q46881122 | ||
| P433 | issue | 4 | |
| P921 | main subject | hypogonadism | Q938107 |
| P304 | page(s) | 187-197 | |
| P577 | publication date | 2012-10-15 | |
| P1433 | published in | The Aging Male | Q7712900 |
| P1476 | title | How to help the aging male? Current approaches to hypogonadism in primary care | |
| P478 | volume | 15 |
| Q42326501 | Approaches to male hypogonadism in primary care |
| Q50662671 | Association between testosterone levels and the metabolic syndrome in adult men. |
| Q64062928 | Bowel preparation for colonoscopy may decrease the levels of testosterone in Korean men |
| Q38873488 | Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study). |
| Q58136346 | Identification and treatment of older persons with sarcopenia |
| Q89336513 | Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men |
| Q37686901 | Quality of Life and Sexual Health in the Aging of PCa Survivors |
| Q36287950 | Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. |
| Q53100434 | Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. |
| Q64245432 | The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism |
| Q36246687 | The prevalence of the metabolic syndrome in a farm worker community in the Boland district, South Africa |
| Q58140620 | The relationship between testosterone, metabolic syndrome, and mean carotid intima-media thickness in aging men |
| Q37639188 | The role of hypogonadism in Klinefelter syndrome. |
| Q35257451 | Three and six grams supplementation of d-aspartic acid in resistance trained men. |
Search more.